ANIMAL MODEL MARKET ANALYSIS

Animals are good research subjects for a variety of reasons. They are biologically similar to humans and susceptible to many of the same health problems. An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans. It's a tool that researchers use to study diseases and test treatments in cases where human experimentation is not possible and/or unethical. Animal models generate hypotheses as to the developmental, molecular, cellular or physiological effects of a gene on human behavior. Mice and rats make up approximately 95% of all laboratory animals, with mice the most commonly used animal in biomedical research.

Market Statistics:

The global animal model market was valued at US$ 1,577.30 Mn in 2021 and is forecast to reach a value of US$ 2,394.30 Mn by 2028 at a CAGR of 6.0% between 2022 and 2028.

North America held dominant position in the global animal model market in 2022, accounting for 37.8% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Animal Model Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Recent Developments:

In October 2020, Taconic Biosciences announced the launch of its first hACE2 model. AC70 mouse experiences a lethal response to SARS-CoV-2 (COVID-19). The new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.

In March 2020, Crown Bioscience launched two new liver fibrosis rodent models, allowing more rapid and cost- effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.

Market Drivers:

1. Rise in usage of animal models in pre-clinical development by several research laboratories and biopharmaceutical industries is expected to augment the growth of the global animal model market during the forecast period. For example, in December 2021, World Health Organization (WHO) launched the SARS-CoV-2 Omicron variant assays and animal models study tracker, even as the highly mutant variant is spreading fast across the globe. WHO is already conducting research studies on variants of the SARS-CoV2 virus.
2. Increasing implications of mouse clinical trials for more predictive outcomes is expected to boost the growth of the global animal model market during the forecast period. For example, in January 2020, Taconic Biosciences (Taconic Farms, Inc.), a global leader in providing drug discovery animal model solutions, expanded its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.

Figure 2. Global Animal Model Market Share (%), by Animal Type, 2022

To learn more about this report, request a free sample copy

Market Restraints:

1. Strict regulations and guidelines is expected to hamper growth of the global animal model market. For example, implementation of laws and regulations for animal protection and welfare has led to restrictive practices and restrictions on the use of animals for various purposes. Many countries worldwide have banned the usage of animal models.
2. Growing opposition on animal testing by several organizations is expected to hinder growth of the global animal model market. There are many organizations worldwide that are against animal testing. Moreover, a Pew Research Center poll found that around 52% of U.S. adults oppose the use of animal models in scientific research.

Market Opportunities:

1. The outbreak of COVID-19 is expected to offer significant growth opportunities for players in the global animal model market. For instance, in April 2021, Taconic Biosciences announced the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit. hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.
2. Increasing number of research and development activities are expected to provide lucrative growth opportunities for players in the global animal model market. For instance, according to the WHO, between 1999 and 2021, the U.S. had the highest total number of trials (157,618), followed by China (80,333) and Japan (57,754). Moreover, in 2021, the U.S. and Germany led R&D (research and development) funding followed by a high-income country for COVID-19 vaccine related research activities.

Market Trends/Key Takeaways:

1. Large number of applications in healthcare domain and physiological similarities between human and animal is expected to accelerate growth of the global animal model market during the forecast period. For example, in September 2020, Charles River's Research Models and Services division launched digital animal model ordering platform for North America. It is a giant step to reduce the risk of human error, improve operational communication, and give us better insight into how we can better serve the research community.
2. Growing consumption of personalized medicine is expected to propel growth of the global animal model market over the forecast period. For example, the National Precision Medicine program and the Three Beyonds program were launched in Singapore for promoting the uptake of new technologies and digital infrastructure for supporting personalized healthcare.

Competitive Landscape:

Company Profiles:

1. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
2. ENVIGO
3. EUROFINS SCIENTIFIC SE
4. GENOWAY S.A.
5. HERA BIOLABS (TRANSPOSAGEN BIOPHARMACEUTICALS)
6. JSR CORPORATION (CROWN BIOSCIENCE INC.)
7. OZGENE PTY LTD.
8. PERKINELMER, INC. (HORIZON DISCOVERY GROUP PLC.)
9. TACONIC BIOSCIENCES
10. THE JACKSON LABORATORY